Literature DB >> 8758207

Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas.

C Kenck1, M Wilhelm, P Bugert, G Staehler, G Kovacs.   

Abstract

To define the possible role of the VHL gene in the development of sporadic renal cell carcinomas, 91 different parenchymal tumours of the kidney have been investigated for mutation of the VHL gene by single strand conformation polymorphism (SSCP) and/or heteroduplex (HD) techniques. Chromosome 3p deletion was detected in 98 per cent of non-papillary renal cell carcinomas and in 25 per cent of chromophobe renal cell carcinomas. In 22 of the 43 non-papillary renal cell carcinomas, abnormally migrating DNA bands were detected by SSCP and/or HD analysis. No mobility shift was seen in any of the 23 chromophobe renal cell carcinomas. In addition, 15 papillary renal cell tumours and ten renal oncocytomas, which are characterized by genetic changes other than loss of chromosome 3p sequences, were analysed for mutation of the VHL gene. None of these tumours showed abnormal migration patterns. The results indicate that mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8758207     DOI: 10.1002/(SICI)1096-9896(199606)179:2<157::AID-PATH557>3.0.CO;2-S

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

1.  Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.

Authors:  Chao-Nan Qian; Kyle A Furge; Jared Knol; Dan Huang; Jindong Chen; Karl J Dykema; Eric J Kort; Aaron Massie; Sok Kean Khoo; Kristin Vanden Beldt; James H Resau; John Anema; Richard J Kahnoski; Hans Morreau; Philippe Camparo; Eva Comperat; Mathilde Sibony; Yves Denoux; Vincent Molinie; Annick Vieillefond; Charis Eng; Bart O Williams; Bin Tean Teh
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

Review 2.  Renal cell carcinoma.

Authors:  Paul Cairns
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 3.  Future directions in renal cell carcinoma: 2011 and beyond.

Authors:  Daniel C Cho; Michael B Atkins
Journal:  Hematol Oncol Clin North Am       Date:  2011-08       Impact factor: 3.722

4.  Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.

Authors:  Alison C Young; Rachel A Craven; Dena Cohen; Claire Taylor; Christopher Booth; Patricia Harnden; David A Cairns; Dewi Astuti; Walter Gregory; Eamonn R Maher; Margaret A Knowles; Adrian Joyce; Peter J Selby; Rosamonde E Banks
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

5.  The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.

Authors:  Daniel C Cho; Matthew B Cohen; David J Panka; Michael Collins; Musie Ghebremichael; Michael B Atkins; Sabina Signoretti; James W Mier
Journal:  Clin Cancer Res       Date:  2010-07-06       Impact factor: 12.531

6.  Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions.

Authors:  Daniel Y C Heng; Christian Kollmannsberger; Kim N Chi
Journal:  Ther Adv Med Oncol       Date:  2010-01       Impact factor: 8.168

7.  Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression.

Authors:  Peter Schraml; Alexander Hergovich; Florian Hatz; Mahul B Amin; So D Lim; Wilhelm Krek; Michael J Mihatsch; Holger Moch; Alexander Hergovitz
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

8.  Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma.

Authors:  Kyle A Furge; Karl Dykema; David Petillo; Michael Westphal; Zhongfa Zhang; Eric J Kort; Bin Tean Teh
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

9.  Genome-wide prediction of splice-modifying SNPs in human genes using a new analysis pipeline called AASsites.

Authors:  Kirsten Faber; Karl-Heinz Glatting; Phillip J Mueller; Angela Risch; Agnes Hotz-Wagenblatt
Journal:  BMC Bioinformatics       Date:  2011-07-05       Impact factor: 3.169

10.  Designing clinical trials for kidney cancer based on newly developed prognostic and predictive tools.

Authors:  Daniel Cho; David McDermott; Michael Atkins
Journal:  Curr Urol Rep       Date:  2006-01       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.